SHANGHAI MICROPORT ENDOVASCULAR MED revenue breakdown overview

SHANGHAI MICROPORT ENDOVASCULAR MED revenue for the last year amounted to 1.21 B CNY, the most of which — 904.33 M CNY — came from its highest performing source at the moment, Aortic Stents, the year earlier bringing 939.85 M CNY. The greatest contribution to the revenue figure was made by China — last year it brought SHANGHAI MICROPORT ENDOVASCULAR MED 1.04 B CNY, and the year before that — 1.10 B CNY.